NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 5 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Q2 FY27 Call: Revenue at Record ₹79.5 Cr, Reallocates ₹48.1 Cr IPO Funds to Own Facilities
Laxmi Dental released its Q2 FY27 earnings call transcript reporting record quarterly revenue of ₹79.5 crore and an EBITDA margin of 19.2%. EBITDA grew 38.5% YoY while PAT increased 17.6% YoY to deliver a 12.6% PAT margin. The company received shareholder approval to redirect ₹48.1 crore of unutilized IPO funds toward constructing integrated manufacturing infrastructure across FY27 and FY28. Segmentally, the dental lab division grew 22.7% YoY, led by a 32% surge in international labs, and clear aligners grew 23.5% YoY.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the formal transcript for the Q2 FY27 post-earnings conference call held on November 04, 2026.
ஏன் இது முக்கியம்Management confirmed operational scaling and strategic shift to move from leased multi-floor units in Mira Road to a consolidated self-owned manufacturing facility, which will absorb ~16.8% of net worth in capex.
Q2 FY27 Revenue: ₹79.5 கோடிQ2 FY27 EBITDA Margin: 19.2%Q2 FY27 PAT Margin: 12.6%Unutilized IPO funds redeployed: ₹48.1 கோடிCapex plan vs Net Worth (₹259 Cr): ~18.6%
📅 குறுகிய காலம்Earnings transcript reinforces strong Q2 momentum across international labs and aligners, though direct scanner hardware sales slowed to ₹3.5 crore vs ₹8.9 crore YoY as the model transitions to subscriptions.
📈 நீண்ட காலம்Consolidating operations into an owned, horizontally integrated plant and scaling locked digital scanners can enhance operating leverage, margins, and recurring laboratory volumes.
⚠ அபாய எச்சரிக்கைகள்
Execution and transition risk during the migration from leased Mira Road facilities to the new plant
Near-term revenue drag from scanner sales shifting from upfront capital sales to a monthly subscription model
👀 கவனிக்க வேண்டியவை
Track the deployment timeline and construction milestones for the new ₹48.1 crore integrated facility across FY27-FY28, alongside adoption rates of the newly launched locked-scanner subscription model.
Laxmi Dental's 60% JV Kids-e-Dental Receives EU MDR and ISO 13485 Certifications
Laxmi Dental Limited announced that its 60%-owned jointly controlled entity, Kids-e-Dental LLP (KED), has received the EU Quality Management System Certificate under EU MDR Regulation 2017/745 and ISO 13485:2016 from TÜV SÜD. The EU MDR Class IIa certification is valid from November 4, 2026, until November 3, 2031, covering 7 paediatric and dental devices including Bioflx crown and Kids-e-crown. This enables KED to commercially market these dental products across the European Union and European Economic Area upon completing regulatory formalities. The ISO 13485 certificate is valid through November 3, 2029.
உச்சம் நம்பிக்கை
என்ன மாறியதுKids-e-Dental LLP obtained official EU MDR and ISO quality certifications issued by TÜV SÜD.
ஏன் இது முக்கியம்Opens up the European Union and EEA markets for KED's pediatric dental line, supporting Laxmi Dental's international expansion strategy beyond domestic and US operations.
Laxmi Dental stake in Kids-e-Dental: 60%EU MDR certificate validity: November 4, 2026 until November 3, 2031ISO 13485 validity: November 4, 2026 until November 3, 2029Number of covered products: 7
📅 குறுகிய காலம்Positive sentiment for export prospects; however, immediate revenue contribution depends on distributor onboarding and rollout in EU member states.
📈 நீண்ட காலம்Strengthens the company's high-margin international export basket and expands its addressable market for paediatric dental solutions.
⚠ அபாய எச்சரிக்கைகள்
Execution risk on international distribution and sales ramp-up
Subject to periodic regulatory surveillance audits by TÜV SÜD
👀 கவனிக்க வேண்டியவை
Track management commentary in upcoming earnings calls regarding commercial launch timelines and export distribution partnerships in the EU/EEA.
Laxmi Dental Q2 FY27 Net Profit Up 17.6% YoY to ₹10.04 Cr, Revenue Rises 10% to ₹79.5 Cr
Laxmi Dental reported its highest-ever quarterly revenue of ₹79.52 Cr for Q2 FY27, up 10.0% YoY, driven by broad-based growth in core dental products. EBITDA rose 38.5% YoY to ₹15.27 Cr with margins expanding 390 bps to 19.2%. Consolidated PAT (after JVs) reached ₹10.04 Cr, growing 17.6% YoY. Scanner sales saw a decline to ₹3.5 Cr versus ₹8.9 Cr last year, while the dental lab and aligner businesses posted robust YoY revenue growth of 22.7% and 23.5%, respectively.
உச்சம் நம்பிக்கை
என்ன மாறியதுLaxmi Dental released its earnings press release reporting record quarterly revenues and strong operating margins for Q2 FY27.
ஏன் இது முக்கியம்Demonstrates operating leverage and pricing discipline in core lab and aligner exports, even as scanner equipment sales experienced a temporary drop.
Revenue from operations (Q2 FY27): ₹795.2 MnEBITDA (Q2 FY27): ₹152.7 MnEBITDA லாப வரம்பு: 19.2%PAT after share of JVs: ₹100.4 MnIPO proceeds redeployed to facility: ₹26.9 கோடி
📅 குறுகிய காலம்Solid operational expansion and record quarterly numbers could provide support following recent stock weakness.
📈 நீண்ட காலம்Redeployment of ₹48.1 Cr IPO proceeds into integrated facilities along with international expansion under global trade arrangements supports structural growth.
⚠ அபாய எச்சரிக்கைகள்
Drop in intra-oral scanner sales to ₹3.5 Cr from ₹8.9 Cr YoY
Exposure to trade tariffs and international market volatility
👀 கவனிக்க வேண்டியவை
Track the deployment of ₹26.9 Cr unutilised IPO proceeds towards the planned integrated lab facility and monitor scanner sales recovery under the new subscription model.
Laxmi Dental Limited announced its financial results for the quarter and half-year ended September 30, 2026. The Board reviewed unaudited consolidated results where five reporting subsidiaries generated revenue of ₹33.26 Cr (175.53 million for Q2) and net profit of ₹4.60 Cr for H1. Additionally, the company disclosed the variation of IPO objects approved by shareholders, reallocating ₹48.10 Cr towards land acquisition, plant construction, and movable assets, with ₹46.76 Cr remaining unutilised and parked in fixed deposits as of September 30, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுLaxmi Dental submitted its unaudited Q2/H1 FY27 financial results and provided an update on the revised deployment of IPO proceeds.
ஏன் இது முக்கியம்Clarifies the deployment of ₹46.76 Cr unspent IPO capital towards physical manufacturing capacity and aligner facilities across FY27 and FY28.
Unutilised IPO proceeds: INR 467.60 millionTotal IPO proceeds raised: INR 1,281.70 millionReallocated funds for new objects: INR 481.03 millionSubsidiaries H1 revenue: INR 332.55 million
📅 குறுகிய காலம்Market reaction will likely focus on full consolidated top-line and margin trajectory as detailed disclosures become accessible.
📈 நீண்ட காலம்Reallocation of funds to construct a dedicated manufacturing facility for dental laboratory and aligners supports long-term volume scaling.
⚠ அபாய எச்சரிக்கைகள்
Pending regulatory approval from Regional Director for the Bizdent Devices merger
Potential ongoing adjustments from the New Labour Codes
👀 கவனிக்க வேண்டியவை
Track the deployment timeline of the remaining ₹46.76 Cr capex for the manufacturing plant and the Regional Director's approval for the Bizdent Devices merger.
US Subsidiary Receives $0.63M (₹5.92 Cr) Tariff Refund from US Customs
Laxmi Dental Limited announced that its US subsidiary, Laxmi Dental Lab USA, INC, received a tariff refund of US$ 0.63 million (approx. ₹59.20 million / ₹5.92 crore) from U.S. Customs and Border Protection. This follows directives from the US Supreme Court ordering the US Government to refund excess tariffs collected from importers. The refund provides a direct one-off cash inflow, representing roughly 19% of the company's TTM net profit of ₹31 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுUS Customs has refunded ₹5.92 crore in previously collected excess import tariffs to Laxmi Dental's US subsidiary.
ஏன் இது முக்கியம்The refund directly returns cash to the company after historical US tariffs previously depressed operating margins by an estimated 90 bps.
Tariff refund (USD): US$ 0.63 millionTariff refund (INR): approximately INR 59.20 millionRefund vs TTM PAT: ~19.1%Refund vs TTM Revenue: ~2.1%
📅 குறுகிய காலம்Positive sentiment from an unexpected one-time cash receipt and potential earnings boost in the current quarter.
📈 நீண்ட காலம்Provides clarity and relief around historical US trade tariffs, supporting margin stability for export operations.
⚠ அபாய எச்சரிக்கைகள்
One-time non-recurring financial gain
Future US trade policy and tariff fluctuations remain an ongoing industry risk
👀 கவனிக்க வேண்டியவை
Monitor how this one-off inflow is recognized in upcoming Q3 FY27 financial results and whether reduced tariff burdens permanently improve international operating margins going forward.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Laxmi Dental seeks nod to reallocate ₹48.1 Cr unutilised IPO funds for new plant capex
Laxmi Dental has issued its 22nd AGM notice scheduled for September 25, 2026, seeking shareholder approval to vary the utilisation of IPO proceeds. Out of total IPO proceeds of ₹128.17 Cr (INR 1,281.70 Mn), ₹80.07 Cr (62.47%) has been utilised as of August 18, 2026. The company proposes to reallocate the remaining unutilised ₹48.10 Cr towards land acquisition and construction of a dental laboratory and aligner facility (₹26.90 Cr) and equipment/machinery (₹21.21 Cr). The revised deployment is slated across FY27 and FY28, requiring a 90% voting threshold to take effect.
உச்சம் நம்பிக்கை
என்ன மாறியதுLaxmi Dental is redirecting ₹48.10 Cr of unutilised IPO proceeds from standalone machinery purchases towards acquiring land, building civil infrastructure, and equipping a new dental aligner and lab plant.
ஏன் இது முக்கியம்The reallocation shifts capital deployment towards building an owned, integrated manufacturing facility by FY28, providing physical capacity to scale high-margin aligner and laboratory products.
Total IPO proceeds: INR 1,281.70 millionUtilised amount (62.47%): INR 800.67 millionReallocated capex amount: INR 481.03 millionLand and construction allocation: INR 268.96 millionMachinery & equipment allocation: INR 212.07 millionReallocated capex vs TTM revenue: ~16.8%
📅 குறுகிய காலம்Near-term impact is administrative; attention remains on shareholder approval at the AGM on September 25, 2026.
📈 நீண்ட காலம்Setting up an integrated manufacturing facility across FY27-FY28 supports the company's 20-25% structural revenue growth targets and aligner business scaling.
⚠ அபாய எச்சரிக்கைகள்
Resolution requires a high approval threshold of >=90% of votes cast to be implemented
Execution risks including land due diligence, regulatory approvals, and civil construction timelines
👀 கவனிக்க வேண்டியவை
Track the e-voting results post the September 25, 2026 AGM to confirm the 90% voting approval, followed by execution of definitive land acquisition agreements.
Laxmi Dental Limited's Board of Directors met on August 27, 2026, and approved a proposed variation in the objects of its IPO proceeds along with an extension of the timeline for utilization, subject to shareholder approval. The Board also approved the allotment of 7,911 equity shares of face value INR 2 each under the Laxmi Dental Stock Option Scheme 2024. Consequently, the company's paid-up equity share base expanded marginally from 5,50,21,509 to 5,50,29,420 shares. Detailed rationale and revised allocations regarding the IPO proceeds will be provided in the upcoming shareholder notice.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe Board approved the allotment of 7,911 ESOP shares and proposed modifying the objects and utilization schedule of its IPO proceeds.
ஏன் இது முக்கியம்Changes to IPO fund utilization timelines or objectives can alter planned project execution schedules and cash deployment efficiency.
📅 குறுகிய காலம்Market attention will shift to the detailed explanatory statement to see which projects face timeline extensions or budget reallocations.
📈 நீண்ட காலம்Delays or shifts in capital expenditure funded by IPO proceeds could push back expected operational milestones and capacity timelines.
⚠ அபாய எச்சரிக்கைகள்
Uncertainty around the redeployment or delayed deployment of IPO proceeds
Minor equity dilution from ESOP allotment
👀 கவனிக்க வேண்டியவை
Review the upcoming shareholder notice and explanatory statement to assess the revised capital allocation schedule and reasons for altering IPO fund deployment.
Laxmi Dental reallocates ₹48.1 Cr unutilized IPO proceeds for new plant construction by FY28
Laxmi Dental's Board approved a variation in its IPO proceeds utilization, reallocating ₹48.10 Cr (INR 481.03 million) of unutilized funds toward land acquisition, facility construction, and equipment. Out of ₹128.17 Cr raised, the company has utilized ₹80.07 Cr (62.47%) as of August 18, 2026. The remaining funds are earmarked for a dental laboratory and aligner facility across FY27 and FY28, subject to shareholder approval. Additionally, 7,911 ESOP shares were allotted.
உச்சம் நம்பிக்கை
என்ன மாறியதுLaxmi Dental modified its IPO object to establish an integrated manufacturing plant (land, building, and machinery) instead of standalone machinery purchases, extending deployment into FY27-FY28.
ஏன் இது முக்கியம்The ₹48.10 Cr capex reallocation represents ~16.8% of TTM revenue (₹287 Cr) and will support long-term capacity expansion for clear aligners and dental laboratory products.
📅 குறுகிய காலம்Shareholders will vote on the proposed variation; trading window remains closed until 48 hours post-AGM results.
📈 நீண்ட காலம்Setting up a dedicated manufacturing facility for dental aligners and lab products is expected to strengthen production scale and margin profile as Bizdent is fully amalgamated.
⚠ அபாய எச்சரிக்கைகள்
Execution timeline risks associated with land due diligence, regulatory approvals, and construction milestones
Shareholder approval is required for the object variation
👀 கவனிக்க வேண்டியவை
Track shareholder voting approval at the upcoming AGM and monitor updates on definitive agreements for land acquisition following the executed Letter of Intent.
Q1 FY27 PAT Rises 23.8% YoY to ₹10.3 Cr as Revenue Hits Record ₹74.7 Cr
Laxmi Dental released its Q1 FY27 earnings conference call transcript, detailing a record quarterly revenue of ₹74.7 Cr, up 13.9% YoY. Net profit increased 23.8% YoY to ₹10.3 Cr with a 13.8% PAT margin, while EBITDA expanded 20.6% YoY to ₹14.4 Cr (19.2% margin). Growth was propelled by the international lab business (up 37.4% YoY), aligner solutions (up 28.6% YoY), and Kids-e-Dental (up 54.4% YoY). The company has also signed a Letter of Intent (LoI) to acquire land in Palghar, Maharashtra, to transition from leased premises to an owned manufacturing facility.
உச்சம் நம்பிக்கை
என்ன மாறியதுLaxmi Dental conducted its Q1 FY27 earnings call, sharing operational updates including US leadership expansion, international lab traction, and plans to acquire manufacturing land in Palghar.
ஏன் இது முக்கியம்High-margin international lab exports and aligner products are driving margin expansion, while moving to an owned facility will provide cost control and capacity scalability.
📅 குறுகிய காலம்Reflects healthy execution and continuous momentum across core and high-growth dental verticals.
📈 நீண்ட காலம்Transition to owned manufacturing facilities, digital workflow adoption, and deeper US market expansion position the company for sustainable long-term scale.
⚠ அபாய எச்சரிக்கைகள்
Higher other expenses due to freight, provisions, and automation investments
Potential global tariff/trade barriers affecting international sales
👀 கவனிக்க வேண்டியவை
Track progress on the land acquisition and facility setup in Palghar, along with international market penetration following the appointment of the new US CEO.
₹6.21 Cr Land Acquisition LOI and Allotment of 59,360 ESOP Shares
Laxmi Dental Limited has approved the execution of a Letter of Intent (LOI) for the acquisition of land in Palghar, Maharashtra, for a total consideration of ₹6.21 crore. The company also allotted 59,360 equity shares to employees under its ESOP 2024 scheme, resulting in a marginal increase in paid-up capital. Additionally, the board noted the surrender/cancellation of 1,636 employee stock options. These moves indicate a focus on infrastructure expansion and employee retention.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has committed to a ₹6.21 crore land purchase and marginally expanded its equity base through employee stock options.
ஏன் இது முக்கியம்The land acquisition suggests a strategic move toward capacity expansion or new facility development, which is a lead indicator for future growth. The ESOP allotment is a routine compensation mechanism but results in minor equity dilution.
Land Acquisition Consideration: ₹6,21,00,000ESOP Shares Allotted: 59,360Post-Allotment Share Count: 5,50,21,509Options Cancelled: 1,636Face Value per Share: ₹2
📅 குறுகிய காலம்The news is likely to be viewed positively as it signals expansionary intent, though the immediate financial impact is limited to the land outflow.
📈 நீண்ட காலம்The acquisition of land is a structural positive that could lead to increased production capacity in the coming years, depending on the development timeline.
⚠ அபாய எச்சரிக்கைகள்
Execution risk related to the finalization of the land acquisition
👀 கவனிக்க வேண்டியவை
Investors should monitor the transition from the Letter of Intent to a definitive sale deed and the subsequent announcement regarding the intended use (manufacturing vs. logistics) for the Palghar land.
23.8% PAT Growth: Laxmi Dental Reports Record Quarterly Revenue of ₹74.7 Cr in Q1 FY27
Laxmi Dental reported its highest-ever quarterly revenue of ₹74.7 crore for Q1 FY27, a 13.9% YoY increase. Profitability showed strong momentum with PAT rising 23.8% YoY to ₹10.32 crore, while EBITDA margins expanded by 100 bps to 19.2%. Growth was primarily driven by the international dental laboratory segment, which surged 37.4% YoY, and the Aligner Solutions business, which grew 28.6% YoY. The company is strengthening its global footprint by appointing a new CEO for its US operations and establishing three new support facilities in India.
உச்சம் நம்பிக்கை
என்ன மாறியதுLaxmi Dental achieved record quarterly revenue and margin expansion, shifting its product mix toward higher-margin international lab services and aligners.
ஏன் இது முக்கியம்The strong performance in international markets (37.4% growth) validates the company's export-led growth strategy and its ability to maintain high gross margins (78.6%) despite rising freight costs.
📅 குறுகிய காலம்The stock is likely to react positively to the record revenue and margin expansion, reflecting strong operational execution.
📈 நீண்ட காலம்The company's focus on digital dentistry, AI-led automation, and international expansion positions it well to meet its 20-25% growth guidance over the coming years.
⚠ அபாய எச்சரிக்கைகள்
Higher freight costs impacting other expenses
Increased ECL (provisions) noted in the quarter
Potential US tariff impacts on margins (historical 90 bps risk)
👀 கவனிக்க வேண்டியவை
Watch for the execution of the US market strategy under the new CEO and the operational efficiency gains from the three newly established domestic support facilities.
₹74.7 Cr Revenue: Laxmi Dental Reports 13.9% YoY Growth and Margin Expansion in Q1FY27
Laxmi Dental achieved its highest-ever quarterly revenue of ₹74.7 Cr in Q1FY27, a 13.9% YoY increase, driven by strong growth in the Dental Laboratory (+23.5%) and Aligner (+28.6%) segments. Profitability improved significantly with PAT rising 23.8% YoY to ₹10.32 Cr, supported by a better product mix that pushed gross margins to 78.6%. International laboratory operations were a standout, growing 37.4% YoY, while the company strengthened its US leadership with a new CEO appointment. However, scanner sales saw a sharp 62% YoY decline to ₹2.2 Cr, which management attributed to minimal contribution during the quarter.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company achieved record quarterly revenue and significant margin expansion while strengthening its international leadership team and domestic support infrastructure.
ஏன் இது முக்கியம்The results validate the company's integrated dental model and its ability to scale high-margin laboratory and aligner products internationally, offsetting volatility in equipment sales.
Q1FY27 Revenue: ₹74.7 கோடிQ1 வருவாய் vs TTM வருவாய்: 26.87%Gross Margin: 78.6%International Lab Growth: 37.4%Scanner Sales: ₹2.2 கோடிUnutilized IPO Funds: ₹64 கோடி
📅 குறுகிய காலம்The stock may react positively to the record revenue and margin improvement, though the decline in scanner sales warrants caution regarding equipment demand.
📈 நீண்ட காலம்Structural growth remains tied to digital dentistry adoption and international expansion; the company's position as a leading export lab provides a long-term competitive moat.
⚠ அபாய எச்சரிக்கைகள்
Significant 62% decline in scanner sales
Rising employee costs due to US expansion
Exposure to international trade barriers/tariffs
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of the US market strategy under the new leadership and the deployment of ₹64 Cr in unutilized IPO funds for planned automation and capacity expansion.
Laxmi Dental to acquire Palghar land for Rs 6.21 Cr; approves Q1 FY27 results
Laxmi Dental has executed a Letter of Intent to acquire land in Palghar, Maharashtra, for Rs 6.21 Cr to expand manufacturing operations. This investment represents approximately 2.5% of the company's net worth of Rs 247 Cr. The board also approved Q1 FY27 financial results and allotted 59,360 equity shares under its ESOP 2024 scheme, resulting in a marginal 0.1% equity dilution. Five subsidiaries reported a combined revenue of Rs 15.7 Cr and a net profit of Rs 1.75 Cr for the quarter ended June 30, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has initiated a land acquisition for business expansion and slightly increased its share capital through employee stock options.
ஏன் இது முக்கியம்The land acquisition signals the start of planned capacity expansion to meet rising demand, though the current investment is small relative to the company's total market cap of Rs 1160 Cr.
Land Consideration: Rs 6.21 கோடிLand vs Net Worth: ~2.5%ESOP Allotment: 59,360 பங்குகள்Equity Dilution: ~0.1%Subsidiary Revenue (Q1): Rs 15.7 கோடிAdvance Paid: Rs 51 Lakhs
📅 குறுகிய காலம்The market is likely to react neutrally as the land acquisition is small and the ESOP dilution is negligible; focus will remain on the full Q1 FY27 earnings performance.
📈 நீண்ட காலம்The expansion into a new factory at Palghar aligns with the company's strategy to scale its branded portfolio and international penetration, though execution remains key.
⚠ அபாய எச்சரிக்கைகள்
Execution risk for the new factory construction
Potential margin pressure from international trade barriers as noted in historical filings
👀 கவனிக்க வேண்டியவை
Monitor the construction timeline for the Palghar factory and the deployment of the remaining Rs 64 Cr unutilized IPO funds for future capacity expansion.
Laxmi Dental Q4 FY26 Revenue Up 22% YoY to ₹74 Cr; Reports Highest Ever Quarterly Performance
Laxmi Dental Limited delivered its strongest quarterly performance in Q4 FY26, with revenue growing 22% YoY to ₹74 crores and PAT reaching ₹10.1 crores. The growth was primarily driven by a 40.9% YoY surge in the international lab business and a 16.3% rise in domestic operations. Despite external headwinds like US tariffs and global freight volatility, the company improved its EBITDA margin to 18.3% and maintained a debt-free balance sheet with ₹99 crores in cash and investments. The management is aggressively pushing digital dentistry, with digital penetration in the domestic lab business now at 80%.
முக்கிய அம்சங்கள்
Achieved highest-ever quarterly revenue of ₹74 crores, up 21.9% YoY, and annual revenue of ₹277.9 crores.International lab business grew by 40.9% YoY, while the domestic lab segment grew by 16.3%.EBITDA margins expanded to 18.3% in Q4 FY26 from 15.7% in the same period last year.Company remains debt-free with a strong liquidity position of ₹99 crores in cash and bank balances.Digital penetration in the domestic lab business reached 80%, with a medium-term target of 90%.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to maintain high margins while scaling the international business and the adoption rate of its new AI-driven platform, iScope 360. The debt-free status and strong cash position provide significant cushion for future expansion.
Laxmi Dental Q4 FY26: Revenue Up 21.9% to ₹74 Cr, PAT Surges 136% YoY
Laxmi Dental Limited reported its highest-ever quarterly revenue of INR 739.5 Mn in Q4 FY26, representing a 21.9% YoY growth. The company achieved a significant PAT jump of 136.1% YoY to INR 100.9 Mn for the quarter, despite headwinds like US tariffs and geopolitical uncertainties. While full-year FY26 PAT declined 9.2% to INR 289.2 Mn, this was due to a non-comparable high base in FY25 which included a one-time property sale gain of INR 70.3 Mn. The core Dental Laboratory business remains strong with 27% YoY growth in Q4.
முக்கிய அம்சங்கள்
Q4 FY26 Revenue reached a record INR 739.5 Mn, up 21.9% YoY and 12% QoQ.EBITDA margins for Q4 improved to 18.3% from 15.7% YoY, despite a 74 bps impact from US tariffs.Core Dental Laboratory business grew 27% YoY in Q4, driven by domestic recovery and international revenue.Scanner sales, acting as a strategic growth enabler, surged 282% YoY in Q4 to INR 82 Mn.Full-year FY26 revenue stood at INR 2,778.6 Mn, a 16.2% increase over the previous fiscal year.
👀 கவனிக்க வேண்டியவை
Investors should view the strong quarterly recovery and record revenue as a sign of robust demand in digital dentistry and aligner solutions. Monitor the impact of US tariffs and geopolitical freight costs on margins in the coming quarters.
Laxmi Dental reported its highest-ever quarterly revenue of ₹74.0 Cr in Q4FY26, marking a 21.9% YoY growth. Despite geopolitical challenges and higher US tariffs, the company maintained healthy EBITDA margins of 18.3% and PAT margins of 13.6% for the quarter. Full-year FY26 revenue reached ₹278 Cr, supported by strong recovery in domestic business and record international operations. The company is successfully transitioning to digital dentistry with approximately 80% digital penetration in its Indian operations.
முக்கிய அம்சங்கள்
Q4FY26 revenue grew 21.9% YoY to ₹74.0 Cr, driven by a 27% growth in the Dental Laboratory segment.Full-year FY26 revenue stood at ₹278 Cr with a consolidated PAT of ₹28.9 Cr.Digital penetration in the Indian dental business reached ~80%, highlighting a shift towards high-tech dentistry.Scanner sales surged 282% YoY in Q4 to ₹8.2 Cr, acting as a strategic enabler for future lab and aligner growth.EBITDA margins for Q4 improved to 18.3% from 15.7% YoY, despite a 74 bps impact from US tariffs.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to scale its Aligner business and manage international tariff risks. The strong digital adoption and record quarterly performance suggest a positive growth trajectory in the specialized dental healthcare space.
Laxmi Dental FY26 Revenue Grows 22% to ₹2,060M; Q4 Net Profit Jumps 63% YoY
Laxmi Dental reported a strong operational performance for FY26, with annual revenue from operations rising 21.8% to ₹2,060.37 million. Although the reported net profit for the full year decreased to ₹193.37 million from ₹257.75 million due to a high base involving exceptional items in the previous year, the core Profit Before Tax (before exceptional items) surged 50.8% to ₹261.26 million. The fourth quarter showed significant momentum, with net profit rising 62.8% YoY to ₹67.98 million, supported by robust sales growth and improved operational margins.
முக்கிய அம்சங்கள்
Annual Revenue from Operations increased 21.8% YoY to ₹2,060.37 million in FY26.Profit Before Exceptional Items and Tax for the full year grew by 50.8% to ₹261.26 million.Q4 FY26 Net Profit stood at ₹67.98 million, a significant 62.8% increase over ₹41.75 million in Q4 FY25.Total Income for the quarter ended March 31, 2026, reached ₹577.26 million vs ₹448.63 million YoY.Full-year Basic EPS stood at ₹3.52, reflecting the underlying operational strength despite the absence of prior-year exceptional gains.
👀 கவனிக்க வேண்டியவை
Investors should look past the headline net profit decline, which was caused by one-off gains in the previous year, and focus on the 50% growth in core operating profit. The strong Q4 performance and consistent revenue growth suggest a healthy outlook for the company's dental solutions business.
Laxmi Dental Approves Merger with Bizdent Devices and Cancels 32,538 ESOP Options
Laxmi Dental Limited has approved the amalgamation of its wholly-owned subsidiary, Bizdent Devices Private Limited, into itself to simplify group structure and achieve operational synergies. Bizdent specializes in aligners, sleep apnea devices, and sports guards, and the merger is expected to reduce administrative costs and improve financial strength. As Bizdent is a 100% subsidiary, no new shares will be issued, and there will be no change in the shareholding pattern. Additionally, the company reported the cancellation of 32,538 ESOP options and several key management and auditor appointments.
முக்கிய அம்சங்கள்
Approved Scheme of Amalgamation with wholly-owned subsidiary Bizdent Devices Private LimitedForfeiture and cancellation of 32,538 ESOP options reportedNo change in shareholding pattern as the transferor company is a 100% subsidiaryAppointment of Bathiya Advisors LLP as Internal Auditors for FY 2026-27Redesignation of Mr. Mitesh Kariya as Chief Operating Officer – Illusion Dental
👀 கவனிக்க வேண்டியவை
The merger is a positive move for corporate simplification and cost rationalization. Investors should view this as a structural improvement that could lead to better operational margins in the long term.
Laxmi Dental to Merge Subsidiary Bizdent Devices; Appoints New Internal Auditors
Laxmi Dental Limited has approved the merger of its wholly-owned subsidiary, Bizdent Devices Private Limited, into itself to streamline operations and reduce administrative costs. Bizdent Devices specializes in aligners and sleep apnea devices, and its consolidation is expected to create a stronger financial base and eliminate inter-company transactions. As Bizdent is a 100% subsidiary, no new shares will be issued, leaving the parent company's shareholding pattern unchanged. Additionally, the board appointed Bathiya Advisors LLP as Internal Auditors for FY 2026-27 and re-appointed Tax Auditors for FY 2025-26.
முக்கிய அம்சங்கள்
Board approved the Scheme of Amalgamation of Bizdent Devices Private Limited (WOS) with Laxmi Dental Limited.The merger will result in the cancellation of the subsidiary's entire share capital with no new equity issuance.Bathiya Advisors LLP appointed as Internal Auditors for FY 2026-27, effective April 1, 2026.Abhay Subhash & Associates re-appointed as Tax Auditors for the financial year 2025-26.Mr. Mitesh Kariya redesignated as Chief Operating Officer – Illusion Dental to strengthen leadership.
👀 கவனிக்க வேண்டியவை
Investors should view the internal merger as a positive move for operational efficiency and cost rationalization. Monitor the timeline for regulatory approvals from the Regional Director and Stock Exchanges to confirm the completion of the amalgamation.
Laxmi Dental Q3FY26 Revenue Grows 7.1% to ₹66 Cr; US Tariffs Reduced to 25%
Laxmi Dental reported a 7.1% YoY revenue growth to ₹66 crores for Q3FY26, driven by a 25% surge in international lab business. Profitability was temporarily impacted by a 150 bps hit from US tariffs and a one-time exceptional item of ₹5.8 crores related to the new labor code. However, the recent India-US trade deal has halved tariffs from 50% to 25%, which is expected to significantly improve margins in the coming quarters. The company remains debt-free and reported strong recovery trends in January 2026 across all business segments.
முக்கிய அம்சங்கள்
Revenue from operations increased 7.1% YoY to ₹66 crores, with 9MFY26 revenue reaching ₹203.9 crores.US import tariffs reduced from 50% to 25% in February 2026, easing pressure on the international segment.Scanner sales grew by 46% YoY to ₹6.4 crores, supporting the company's digital dentistry mission.Recorded a one-time exceptional expense of ₹5.8 crores due to new labor code and accounting standard requirements.Company is now debt-free, leading to a sharp decline in finance costs to ₹0.3 crore from ₹1.5 crore YoY.
👀 கவனிக்க வேண்டியவை
Investors should focus on the anticipated margin expansion in Q4FY26 as the lower US tariffs and the absence of one-time labor costs take effect. The strong growth in high-tech segments like scanners and international labs makes it a key player to watch in the dental healthcare space.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
